Dalbavancin to facilitate early discharge in the treatment of complex musculoskeletal infections: a multi-centre real-life application
<p>Dalbavancin is a lipoglycopeptide with a half-life of 14 d, significantly reducing the need for daily antibiotic dosing. Although dalbavancin is approved for acute bacterial skin and skin structure infections, its off-label use in complex musculoskeletal infection (MSKI) is increasing. Evid...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Copernicus Publications
2025-03-01
|
| Series: | Journal of Bone and Joint Infection |
| Online Access: | https://jbji.copernicus.org/articles/10/93/2025/jbji-10-93-2025.pdf |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|